查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2067510

肉毒桿菌素製劑市場規模、佔有率和趨勢分析報告：按毒素類型、適應症、最終用途、地區和細分市場預測（2026-2040 年）

Botulinum Toxin Drugs Market Size, Share & Trends Analysis Report By Toxin Type, By Indication, By End Use By Region, And Segment Forecasts, 2026 - 2040
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

肉毒桿菌素製劑市場概述

全球肉毒桿菌毒素產品市場預計在 2025 年達到 99.8077 億美元，預計到 2040 年將達到 305.6076 億美元，2026 年至 2040 年的複合年成長率為 7.75%。

該市場受到對成熟的注射用神經毒素製劑的持續需求的驅動，這些製劑具有可靠的臨床檢驗、可預測的療效和一致的安全性。

這些產品特性支持其在美容和治療領域的廣泛應用，從而鞏固了其在醫療保健領域的穩定使用模式。成熟的配方憑藉其在醫生中的高認可度、標準化的給藥方案以及支持可靠療效的長期臨床證據，持續佔據市場佔有率。此外，領先製造商強大的品牌定位和生命週期管理策略也促進了產品在臨床環境中的持續選擇和重複使用。穩定的生產品質和批間可靠性進一步增強了臨床醫生的信心，支持產品在所有治療環境中不間斷的使用。這些因素共同提升了消費者對產品的信心，並有助於維持其在各種臨床應用中的持續穩定需求。

治療領域的成長主要得益於肉毒桿菌素製劑在慢性偏頭痛、頸部肌張力不全症、痙攣和多汗症等疾病的應用日益廣泛。在這些疾病中，產品的療效、劑量穩定性以及作用持續時間對於臨床應用至關重要。核准適應症的不斷擴展以及強力的上市後臨床證據進一步鞏固了現有製劑在疾病長期管理中的作用。這些因素支持在結構化的醫療保健系統中，各個治療領域持續使用該產品，從而維持穩定的需求。可靠的治療效果和可預測的作用持續時間進一步增強了醫生對在慢性疾病中重複使用肉毒桿菌製劑的信心。這有助於將肉毒桿菌製劑長期整合到標準治療方案中，從而支持持續使用。

產品創新仍然是關鍵的成長要素，製造商正致力於研發新一代配方，以延長作用時間、提高穩定性並最佳化給藥方案。艾伯維、益普生和瑞凡斯治療等公司正在開發和推廣差異化的肉毒桿菌毒素產品，以增強其競爭力並擴大臨床效用。

同時，區域性生產商推出的成本競爭力配方產品，降低了價格敏感型市場中產品的價格，從而提高了產品滲透率。配方的持續改進以及產品處理和儲存方式的逐步最佳化，進一步提升了產品在各種臨床環境下的適用性。這些進步有助於產品更廣泛地應用，並維持市場參與企業之間的競爭優勢。總體而言，市場以產品主導，配方性能、品牌實力和持續創新共同推動永續成長。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章 肉毒桿菌毒素市場：變數、趨勢與範圍

  • 市場譜系展望
  • 市場動態
  • 商業環境分析

第4章：肉毒桿菌製劑市場：按毒素類型分類的業務分析

  • 按毒素類型分類的市場佔有率（2025 年和 2040 年）
  • 市場規模、預測和趨勢分析（按毒素類型分類，2021-2040 年）（分發管瓶數量（千瓶））
  • 已通過核准且市售的毒素類型
  • 新興毒素類型（在研究中）

第5章：肉毒桿菌毒素市場：按適應症分類的業務分析

  • 按適應症分類的市場佔有率，2025 年和 2040 年
  • 市場規模、預測與趨勢分析：按適應症分類，2021-2040 年
  • 美容（化妝品）
  • 治療指徵

第6章：肉毒桿菌製劑市場：依最終用途分類的業務分析

  • 按最終用途分類的市場佔有率，2025 年和 2040 年
  • 市場規模、預測和趨勢分析：按最終用途分類，2021-2040 年
  • 醫院（住院和門診）
  • 專科診所
  • 美容診所/醫療水療連鎖

第7章 肉毒桿菌製劑市場：區域估算與趨勢分析

  • 2025年及2040年區域市佔率分析
  • 區域市場概覽
  • 市場規模、預測與趨勢分析（2021-2040年）
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • UAE
    • 科威特

第8章 競爭情勢

  • 參與企業概況
  • 公司市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介列表
    • AbbVie（Allergan Aesthetics）
    • Ipsen
    • Galderma
    • Merz Pharma
    • Evolus
    • Medytox
    • Hugel
    • Daewoong Pharmaceutical
    • Revance Therapeutics
Product Code: GVR-4-68040-914-6

Botulinum Toxin Drugs Market Summary

The global botulinum toxin drugs market size was estimated at USD 9,980.77 million in 2025 and is projected to reach USD 30,560.76 million by 2040, growing at a CAGR of 7.75% from 2026 to 2040. The market is driven by sustained demand for well-established injectable neurotoxin formulations characterized by strong clinical validation, predictable efficacy, and consistent safety profiles.

These product attributes support widespread adoption across both aesthetic and therapeutic applications, reinforcing stable utilization patterns across healthcare settings. Established formulations continue to dominate market share due to high physician familiarity, standardized dosing protocols, and long-term clinical evidence supporting reliable outcomes. In addition, strong brand positioning and lifecycle management strategies by key manufacturers contribute to continued product preference and repeat utilization across clinical practice. Consistent manufacturing quality and batch reliability further strengthen clinician confidence and support uninterrupted product usage across treatment settings. These factors collectively reinforce product-level trust and contribute to sustained demand stability across diverse clinical applications.

Therapeutic growth is supported by the expanding use of botulinum toxin products in conditions such as Chronic Migraine, Cervical Dystonia, Spasticity, and Hyperhidrosis, where product-level efficacy, dosing consistency, and durability of response are critical to clinical adoption. Continued expansion of approved indications and strong post-market clinical evidence reinforce the role of established formulations in long-term disease management. These factors support consistent product utilization and maintain stable demand across therapeutic segments within structured healthcare systems. Reliable treatment outcomes and predictable response duration further enhance physician confidence in repeated administration across chronic conditions. This reinforces long-term integration of botulinum toxin products into standard therapeutic protocols and supports sustained utilization patterns.

Product innovation remains a key growth driver, with manufacturers focusing on next-generation formulations offering extended duration of action, improved stability, and enhanced administration profiles. Companies such as AbbVie, Ipsen, and Revance Therapeutics are advancing differentiated toxin products to strengthen competitive positioning and expand clinical utility.

At the same time, the entry of cost-competitive formulations from regional manufacturers is improving affordability and expanding product penetration in price-sensitive markets. Ongoing formulation refinement and incremental improvements in product handling and storage are further enhancing usability across clinical environments. These advancements support wider adoption and sustain competitive differentiation among market participants. Overall, the market reflects a product-driven landscape where formulation performance, brand strength, and incremental innovation collectively drive sustained growth.

Global Botulinum Toxin Drugs Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2040. For this study, Grand View Research has segmented the global botulinum toxin drugs market report based on toxin type, indication, end use, and region:

  • Toxin Type Outlook (Volume, Number of Vials Dispensed 000's; Revenue, USD Million, 2021 - 2040)
  • Approved & Marketable Toxin Type
    • Type A Botulinum Toxin
    • Type B Botulinum Toxin
  • Emerging Toxin Types (Pipeline)
    • Type E Botulinum Toxin (e.g., BoNT-E)
    • Recombinant Botulinum Toxin
    • Pure Toxin (150 kDa)
    • Liquid Botulinum Toxins (ready-to-use formulations)
    • Innotox
    • Alluzience
    • Relfydess
  • Indication Outlook (Volume, Number of Vials Dispensed 000's; Revenue, USD Million, 2021 - 2040)
  • Aesthetic (Cosmetic)
    • Glabellar lines
    • Forehead lines
    • Crow's feet
    • Facial contouring / masseter reduction
    • Dermotoxin
  • Therapeutic Indications
    • Chronic Migraine
    • Spasticity
    • Cervical Dystonia
    • Blepharospasm
    • Overactive Bladder
    • Hyperhidrosis
    • Ophthalmology
    • Pain Management
    • Others
  • End Use Outlook (Volume, Number of Vials Dispensed 000's; Revenue, USD Million, 2021 - 2040)
  • Hospitals (Inpatient & Outpatient Care)
  • Specialist Clinics
  • Aesthetic Clinics / MedSpa Chains
  • Regional Outlook (Volume, Number of Vials Dispensed 000's; Revenue, USD Million, 2021 - 2040)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Toxin type
    • 1.2.2. Indication
    • 1.2.3. End Use
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Botulinum Toxin Drugs Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Botulinum Toxin Drugs Market: Toxin Type Business Analysis

  • 4.1. Toxin Type Market Share, 2025 & 2040
  • 4.2. Toxin Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Toxin type, 2021 to 2040 (USD Million) (Number of Vials Dispensed (000's))
  • 4.4. Approved & Marketable Toxin Type
    • 4.4.1. Approved & Marketable Toxin Type Market, 2021 - 2040 (USD Million) (Number of Vials Dispensed (000's))
    • 4.4.2. Type A Botulinum Toxin
      • 4.4.2.1. Type A Botulinum Toxin Drugs Market, 2021 - 2040 (USD Million) (Number of Vials Dispensed (000's))
    • 4.4.3. Type B Botulinum Toxin
      • 4.4.3.1. Type B Botulinum Toxin Drugs Market, 2021 - 2040 (USD Million) (Number of Vials Dispensed (000's))
  • 4.5. Emerging Toxin Types (Pipeline)
    • 4.5.1. Emerging Toxin Types (Pipeline) Market, 2021 - 2040 (USD Million) (Number of Vials Dispensed (000's))
    • 4.5.2. Type E Botulinum Toxin (e.g., BoNT-E)
      • 4.5.2.1. Type E Botulinum Toxin (e.g., BoNT-E) Market, 2021 - 2040 (USD Million) (Number of Vials Dispensed (000's))
    • 4.5.3. Recombinant Botulinum Toxin
      • 4.5.3.1. Recombinant Botulinum Toxin Drugs Market, 2021 - 2040 (USD Million) (Number of Vials Dispensed (000's))
    • 4.5.4. Pure Toxin (150 kDa)
      • 4.5.4.1. Pure Toxin (150 kDa) Market, 2021 - 2040 (USD Million) (Number of Vials Dispensed (000's))
    • 4.5.5. Liquid Botulinum Toxins (ready-to-use formulations)
      • 4.5.5.1. Liquid Botulinum Toxins (ready-to-use formulations) Market, 2021 - 2040 (USD Million) (Number of Vials Dispensed (000's))
      • 4.5.5.2. Innotox
        • 4.5.5.2.1. Innotox Market, 2021 - 2040 (USD Million) (Number of Vials Dispensed (000's))
      • 4.5.5.3. Alluzience
        • 4.5.5.3.1. Alluzience Market, 2021 - 2040 (USD Million) (Number of Vials Dispensed (000's))
      • 4.5.5.4. Relfydess
        • 4.5.5.4.1. Relfydess Market, 2021 - 2040 (USD Million) (Number of Vials Dispensed (000's))

Chapter 5. Botulinum Toxin Drugs Market: Indication Business Analysis

  • 5.1. Indication Market Share, 2025 & 2040
  • 5.2. Indication Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2040 (USD Million)
  • 5.4. Aesthetic (Cosmetic)
    • 5.4.1. Aesthetic (Cosmetic) Market, 2021 - 2040 (USD Million)
    • 5.4.2. Glabellar Lines
      • 5.4.2.1. Glabellar Lines Market, 2021 - 2040 (USD Million)
    • 5.4.3. Forehead Lines
      • 5.4.3.1. Forehead Lines Market, 2021 - 2040 (USD Million)
    • 5.4.4. Crow's Feet
      • 5.4.4.1. Crow's Feet Market, 2021 - 2040 (USD Million)
    • 5.4.5. Facial Contouring / Masseter Reduction
      • 5.4.5.1. Facial Contouring / Masseter Reduction Market, 2021 - 2040 (USD Million)
    • 5.4.6. Dermotoxin
      • 5.4.6.1. Dermotoxin Market, 2021 - 2040 (USD Million)
  • 5.5. Therapeutic Indications
    • 5.5.1. Therapeutic Indications Market, 2021 - 2040 (USD Million)
    • 5.5.2. Chronic Migraine
      • 5.5.2.1. Chronic Migraine Market, 2021 - 2040 (USD Million)
    • 5.5.3. Spasticity
      • 5.5.3.1. Spasticity Market, 2021 - 2040 (USD Million)
    • 5.5.4. Cervical Dystonia
      • 5.5.4.1. Cervical Dystonia Market, 2021 - 2040 (USD Million)
    • 5.5.5. Blepharospasm
      • 5.5.5.1. Blepharospasm Market, 2021 - 2040 (USD Million)
    • 5.5.6. Overactive Bladder
      • 5.5.6.1. Overactive Bladder Market, 2021 - 2040 (USD Million)
    • 5.5.7. Hyperhidrosis
      • 5.5.7.1. Hyperhidrosis Market, 2021 - 2040 (USD Million)
    • 5.5.8. Ophthalmology
      • 5.5.8.1. Ophthalmology Market, 2021 - 2040 (USD Million)
    • 5.5.9. Pain Management
      • 5.5.9.1. Pain Management Market, 2021 - 2040 (USD Million)
    • 5.5.10. Others
      • 5.5.10.1. Others Market, 2021 - 2040 (USD Million)

Chapter 6. Botulinum Toxin Drugs Market: End Use Business Analysis

  • 6.1. End Use Market Share, 2025 & 2040
  • 6.2. End Use Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2021 to 2040 (USD Million)
  • 6.4. Hospitals (Inpatient & Outpatient Care)
    • 6.4.1. Hospitals (Inpatient & Outpatient Care) Market, 2021 - 2040 (USD Million)
  • 6.5. Specialist Clinics
    • 6.5.1. Specialist Clinics Market, 2021 - 2040 (USD Million)
  • 6.6. Aesthetic Clinics / MedSpa Chains
    • 6.6.1. Aesthetic Clinics / MedSpa Chains Market, 2021 - 2040 (USD Million)

Chapter 7. Botulinum Toxin Drugs Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2025 & 2040
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2040
  • 7.4. North America
    • 7.4.1. North America Botulinum Toxin Drugs Market Estimates and Forecasts, By Country, 2021 - 2040 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Target Disease Prevalence
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Framework
      • 7.4.2.5. U.S. Botulinum Toxin Drugs Market Estimates and Forecasts, 2021 - 2040 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Target Disease Prevalence
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Framework
      • 7.4.3.5. Canada Botulinum Toxin Drugs Market Estimates and Forecasts, 2021 - 2040 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Target Disease Prevalence
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Framework
      • 7.4.4.5. Mexico Botulinum Toxin Drugs Market Estimates and Forecasts, 2021 - 2040 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Botulinum Toxin Drugs Market Estimates and Forecasts, 2021 - 2040 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Target Disease Prevalence
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Framework
      • 7.5.2.5. UK Botulinum Toxin Drugs Market Estimates and Forecasts, 2021 - 2040 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Target Disease Prevalence
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Framework
      • 7.5.3.5. Germany Botulinum Toxin Drugs Market Estimates and Forecasts, 2021 - 2040 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Target Disease Prevalence
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Reimbursement Framework
      • 7.5.4.5. France Botulinum Toxin Drugs Market Estimates and Forecasts, 2021 - 2040 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Target Disease Prevalence
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Reimbursement Framework
      • 7.5.5.5. Italy Botulinum Toxin Drugs Market Estimates and Forecasts, 2021 - 2040 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Target Disease Prevalence
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Reimbursement Framework
      • 7.5.6.5. Spain Botulinum Toxin Drugs Market Estimates and Forecasts, 2021 - 2040 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Target Disease Prevalence
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Reimbursement Framework
      • 7.5.7.5. Denmark Botulinum Toxin Drugs Market Estimates and Forecasts, 2021 - 2040 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Target Disease Prevalence
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Reimbursement Framework
      • 7.5.8.5. Sweden Botulinum Toxin Drugs Market Estimates and Forecasts, 2021 - 2040 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Target Disease Prevalence
      • 7.5.9.3. Regulatory Framework
      • 7.5.9.4. Reimbursement Framework
      • 7.5.9.5. Norway Botulinum Toxin Drugs Market Estimates and Forecasts, 2021 - 2040 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Botulinum Toxin Drugs Market Estimates and Forecasts, 2021 - 2040 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Target Disease Prevalence
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Framework
      • 7.6.2.5. Japan Botulinum Toxin Drugs Market Estimates and Forecasts, 2021 - 2040 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Target Disease Prevalence
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Framework
      • 7.6.3.5. China Botulinum Toxin Drugs Market Estimates and Forecasts, 2021 - 2040 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Target Disease Prevalence
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Framework
      • 7.6.4.5. India Botulinum Toxin Drugs Market Estimates and Forecasts, 2021 - 2040 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Target Disease Prevalence
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Framework
      • 7.6.5.5. Australia Botulinum Toxin Drugs Market Estimates and Forecasts, 2021 - 2040 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Target Disease Prevalence
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. Reimbursement Framework
      • 7.6.6.5. South Korea Botulinum Toxin Drugs Market Estimates and Forecasts, 2021 - 2040 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Target Disease Prevalence
      • 7.6.7.3. Regulatory Framework
      • 7.6.7.4. Reimbursement Framework
      • 7.6.7.5. Thailand Botulinum Toxin Drugs Market Estimates and Forecasts, 2021 - 2040 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Botulinum Toxin Drugs Market Estimates and Forecasts, 2021 - 2040 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Target Disease Prevalence
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Reimbursement Framework
      • 7.7.2.5. Brazil Botulinum Toxin Drugs Market Estimates and Forecasts, 2021 - 2040 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Target Disease Prevalence
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Reimbursement Framework
      • 7.7.3.5. Argentina Botulinum Toxin Drugs Market Estimates and Forecasts, 2021 - 2040 (USD Million)
  • 7.8. Middle East and Africa
    • 7.8.1. Middle East and Africa Botulinum Toxin Drugs Market Estimates and Forecasts, 2021 - 2040 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Target Disease Prevalence
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Reimbursement Framework
      • 7.8.2.5. South Africa Botulinum Toxin Drugs Market Estimates and Forecasts, 2021 - 2040 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Target Disease Prevalence
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. Reimbursement Framework
      • 7.8.3.5. Saudi Arabia Botulinum Toxin Drugs Market Estimates and Forecasts, 2021 - 2040 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Target Disease Prevalence
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. Reimbursement Framework
      • 7.8.4.5. UAE Botulinum Toxin Drugs Market Estimates and Forecasts, 2021 - 2040 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Target Disease Prevalence
      • 7.8.5.3. Regulatory Framework
      • 7.8.5.4. Reimbursement Framework
      • 7.8.5.5. Kuwait Botulinum Toxin Drugs Market Estimates and Forecasts, 2021 - 2040 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. AbbVie (Allergan Aesthetics)
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Ipsen
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Galderma
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Merz Pharma
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Evolus
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Medytox
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Hugel
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Daewoong Pharmaceutical
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Revance Therapeutics
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global botulinum toxin Drugs market, by region, 2021 - 2040 (USD Million)
  • Table 4 Global botulinum toxin Drugs market, by toxin type, 2021 - 2040 (USD Million) (Number of Vials Dispensed (000's))
  • Table 5 Global botulinum toxin Drugs market, by indication, 2021 - 2040 (USD Million)
  • Table 6 Global botulinum toxin Drugs market, by end use, 2021 - 2040 (USD Million)
  • Table 7 North America botulinum toxin Drugs market, by country, 2021 - 2040 (USD Million)
  • Table 8 North America botulinum toxin Drugs market, by toxin type, 2021 - 2040 (USD Million) (Number of Vials Dispensed (000's))
  • Table 9 North America botulinum toxin Drugs market, by indication, 2021 - 2040 (USD Million)
  • Table 10 North America botulinum toxin Drugs market, by end use, 2021 - 2040 (USD Million)
  • Table 11 U.S. botulinum toxin Drugs market, by toxin type, 2021 - 2040 (USD Million) (Number of Vials Dispensed (000's))
  • Table 12 U.S. botulinum toxin Drugs market, by indication, 2021 - 2040 (USD Million)
  • Table 13 U.S. botulinum toxin Drugs market, by end use, 2021 - 2040 (USD Million)
  • Table 14 Canada botulinum toxin Drugs market, by toxin type, 2021 - 2040 (USD Million) (Number of Vials Dispensed (000's))
  • Table 15 Canada botulinum toxin Drugs market, by indication, 2021 - 2040 (USD Million)
  • Table 16 Canada botulinum toxin Drugs market, by end use, 2021 - 2040 (USD Million)
  • Table 17 Mexico botulinum toxin Drugs market, by toxin type, 2021 - 2040 (USD Million) (Number of Vials Dispensed (000's))
  • Table 18 Mexico botulinum toxin Drugs market, by indication, 2021 - 2040 (USD Million)
  • Table 19 Mexico botulinum toxin Drugs market, by end use, 2021 - 2040 (USD Million)
  • Table 20 Europe botulinum toxin Drugs market, by country, 2021 - 2040 (USD Million)
  • Table 21 Europe botulinum toxin Drugs market, by toxin type, 2021 - 2040 (USD Million) (Number of Vials Dispensed (000's))
  • Table 22 Europe botulinum toxin Drugs market, by indication, 2021 - 2040 (USD Million)
  • Table 23 Europe botulinum toxin Drugs market, by end use, 2021 - 2040 (USD Million)
  • Table 24 UK botulinum toxin Drugs market, by toxin type, 2021 - 2040 (USD Million) (Number of Vials Dispensed (000's))
  • Table 25 UK botulinum toxin Drugs market, by indication, 2021 - 2040 (USD Million)
  • Table 26 UK botulinum toxin Drugs market, by end use, 2021 - 2040 (USD Million)
  • Table 27 Germany botulinum toxin Drugs market, by toxin type, 2021 - 2040 (USD Million) (Number of Vials Dispensed (000's))
  • Table 28 Germany botulinum toxin Drugs market, by indication, 2021 - 2040 (USD Million)
  • Table 29 Germany botulinum toxin Drugs market, by end use, 2021 - 2040 (USD Million)
  • Table 30 France botulinum toxin Drugs market, by toxin type, 2021 - 2040 (USD Million) (Number of Vials Dispensed (000's))
  • Table 31 France botulinum toxin Drugs market, by indication, 2021 - 2040 (USD Million)
  • Table 32 France botulinum toxin Drugs market, by end use, 2021 - 2040 (USD Million)
  • Table 33 Italy botulinum toxin Drugs market, by toxin type, 2021 - 2040 (USD Million) (Number of Vials Dispensed (000's))
  • Table 34 Italy botulinum toxin Drugs market, by indication, 2021 - 2040 (USD Million)
  • Table 35 Italy botulinum toxin Drugs market, by end use, 2021 - 2040 (USD Million)
  • Table 36 Spain botulinum toxin Drugs market, by toxin type, 2021 - 2040 (USD Million) (Number of Vials Dispensed (000's))
  • Table 37 Spain botulinum toxin Drugs market, by indication, 2021 - 2040 (USD Million)
  • Table 38 Spain botulinum toxin Drugs market, by end use, 2021 - 2040 (USD Million)
  • Table 39 Norway botulinum toxin Drugs market, by toxin type, 2021 - 2040 (USD Million) (Number of Vials Dispensed (000's))
  • Table 40 Norway botulinum toxin Drugs market, by indication, 2021 - 2040 (USD Million)
  • Table 41 Norway botulinum toxin Drugs market, by end use, 2021 - 2040 (USD Million)
  • Table 42 Denmark botulinum toxin Drugs market, by toxin type, 2021 - 2040 (USD Million) (Number of Vials Dispensed (000's))
  • Table 43 Denmark botulinum toxin Drugs market, by indication, 2021 - 2040 (USD Million)
  • Table 44 Denmark botulinum toxin Drugs market, by end use, 2021 - 2040 (USD Million)
  • Table 45 Sweden botulinum toxin Drugs market, by toxin type, 2021 - 2040 (USD Million) (Number of Vials Dispensed (000's))
  • Table 46 Sweden botulinum toxin Drugs market, by indication, 2021 - 2040 (USD Million)
  • Table 47 Sweden botulinum toxin Drugs market, by end use, 2021 - 2040 (USD Million)
  • Table 48 Asia Pacific botulinum toxin Drugs market, by country, 2021 - 2040 (USD Million)
  • Table 49 Asia Pacific botulinum toxin Drugs market, by toxin type, 2021 - 2040 (USD Million) (Number of Vials Dispensed (000's))
  • Table 50 Asia Pacific botulinum toxin Drugs market, by indication, 2021 - 2040 (USD Million)
  • Table 51 Asia Pacific botulinum toxin Drugs market, by end use, 2021 - 2040 (USD Million)
  • Table 52 Japan botulinum toxin Drugs market, by toxin type, 2021 - 2040 (USD Million) (Number of Vials Dispensed (000's))
  • Table 53 Japan botulinum toxin Drugs market, by indication, 2021 - 2040 (USD Million)
  • Table 54 Japan botulinum toxin Drugs market, by end use, 2021 - 2040 (USD Million)
  • Table 55 China botulinum toxin Drugs market, by toxin type, 2021 - 2040 (USD Million) (Number of Vials Dispensed (000's))
  • Table 56 China botulinum toxin Drugs market, by indication, 2021 - 2040 (USD Million)
  • Table 57 China botulinum toxin Drugs market, by end use, 2021 - 2040 (USD Million)
  • Table 58 India botulinum toxin Drugs market, by toxin type, 2021 - 2040 (USD Million) (Number of Vials Dispensed (000's))
  • Table 59 India botulinum toxin Drugs market, by indication, 2021 - 2040 (USD Million)
  • Table 60 India botulinum toxin Drugs market, by end use, 2021 - 2040 (USD Million)
  • Table 61 Australia botulinum toxin Drugs market, by toxin type, 2021 - 2040 (USD Million) (Number of Vials Dispensed (000's))
  • Table 62 Australia botulinum toxin Drugs market, by indication, 2021 - 2040 (USD Million)
  • Table 63 Australia botulinum toxin Drugs market, by end use, 2021 - 2040 (USD Million)
  • Table 64 South Korea botulinum toxin Drugs market, by toxin type, 2021 - 2040 (USD Million) (Number of Vials Dispensed (000's))
  • Table 65 South Korea botulinum toxin Drugs market, by indication, 2021 - 2040 (USD Million)
  • Table 66 South Korea botulinum toxin Drugs market, by end use, 2021 - 2040 (USD Million)
  • Table 67 Thailand botulinum toxin Drugs market, by toxin type, 2021 - 2040 (USD Million) (Number of Vials Dispensed (000's))
  • Table 68 Thailand botulinum toxin Drugs market, by indication, 2021 - 2040 (USD Million)
  • Table 69 Thailand botulinum toxin Drugs market, by end use, 2021 - 2040 (USD Million)
  • Table 70 Latin America botulinum toxin Drugs market, by country, 2021 - 2040 (USD Million)
  • Table 71 Latin America botulinum toxin Drugs market, by toxin type, 2021 - 2040 (USD Million) (Number of Vials Dispensed (000's))
  • Table 72 Latin America botulinum toxin Drugs market, by indication, 2021 - 2040 (USD Million)
  • Table 73 Latin America botulinum toxin Drugs market, by end use, 2021 - 2040 (USD Million)
  • Table 74 Brazil botulinum toxin Drugs market, by toxin type, 2021 - 2040 (USD Million) (Number of Vials Dispensed (000's))
  • Table 75 Brazil botulinum toxin Drugs market, by indication, 2021 - 2040 (USD Million)
  • Table 76 Brazil botulinum toxin Drugs market, by end use, 2021 - 2040 (USD Million)
  • Table 77 Argentina botulinum toxin Drugs market, by toxin type, 2021 - 2040 (USD Million) (Number of Vials Dispensed (000's))
  • Table 78 Argentina botulinum toxin Drugs market, by indication, 2021 - 2040 (USD Million)
  • Table 79 Argentina botulinum toxin Drugs market, by end use, 2021 - 2040 (USD Million)
  • Table 80 Middle East & Africa botulinum toxin Drugs market, by country, 2021 - 2040 (USD Million)
  • Table 81 Middle East & Africa botulinum toxin Drugs market, by toxin type, 2021 - 2040 (USD Million) (Number of Vials Dispensed (000's))
  • Table 82 Middle East & Africa botulinum toxin Drugs market, by indication, 2021 - 2040 (USD Million)
  • Table 83 Middle East & Africa botulinum toxin Drugs market, by end use, 2021 - 2040 (USD Million)
  • Table 84 South Africa botulinum toxin Drugs market, by toxin type, 2021 - 2040 (USD Million) (Number of Vials Dispensed (000's))
  • Table 85 South Africa botulinum toxin Drugs market, by indication, 2021 - 2040 (USD Million)
  • Table 86 South Africa botulinum toxin Drugs market, by end use, 2021 - 2040 (USD Million)
  • Table 87 Saudi Arabia botulinum toxin Drugs market, by toxin type, 2021 - 2040 (USD Million) (Number of Vials Dispensed (000's))
  • Table 88 Saudi Arabia botulinum toxin Drugs market, by indication, 2021 - 2040 (USD Million)
  • Table 89 Saudi Arabia botulinum toxin Drugs market, by end use, 2021 - 2040 (USD Million)
  • Table 90 UAE botulinum toxin Drugs market, by toxin type, 2021 - 2040 (USD Million) (Number of Vials Dispensed (000's))
  • Table 91 UAE botulinum toxin Drugs market, by indication, 2021 - 2040 (USD Million)
  • Table 92 UAE botulinum toxin Drugs market, by end use, 2021 - 2040 (USD Million)
  • Table 93 Kuwait botulinum toxin Drugs market, by toxin type, 2021 - 2040 (USD Million) (Number of Vials Dispensed (000's))
  • Table 94 Kuwait botulinum toxin Drugs market, by indication, 2021 - 2040 (USD Million)
  • Table 95 Kuwait botulinum toxin Drugs market, by end use, 2021 - 2040 (USD Million)

List of Figures

  • Fig. 1 Botulinum toxin Drugs market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Competitive landscape
  • Fig. 10 Botulinum toxin Drugs market dynamics
  • Fig. 11 Botulinum toxin Drugs market: Porter's five forces analysis
  • Fig. 12 Botulinum toxin Drugs market: PESTLE analysis
  • Fig. 13 Toxin type market, 2021 - 2040 (USD Million) (Number of Vials Dispensed (000's))
  • Fig. 14 Approved & Marketable Toxin Type market, 2021 - 2040 (USD Million) (Number of Vials Dispensed (000's))
  • Fig. 15 Type A Botulinum Toxin type market, 2021 - 2040 (USD Million) (Number of Vials Dispensed (000's))
  • Fig. 16 Type B Botulinum Toxin type market, 2021 - 2040 (USD Million) (Number of Vials Dispensed (000's))
  • Fig. 17 Emerging Toxin Types (Pipeline) market, 2021 - 2040 (USD Million) (Number of Vials Dispensed (000's))
  • Fig. 18 Type E Botulinum Toxin (eg, BoNT-E) market, 2021 - 2040 (USD Million) (Number of Vials Dispensed (000's))
  • Fig. 19 Recombinant Botulinum Toxin Drugs market, 2021 - 2040 (USD Million) (Number of Vials Dispensed (000's))
  • Fig. 20 Pure Toxin (150 kDa) market, 2021 - 2040 (USD Million) (Number of Vials Dispensed (000's))
  • Fig. 21 Liquid Botulinum Toxins (ready-to-use formulations) market, 2021 - 2040 (USD Million) (Number of Vials Dispensed (000's))
  • Fig. 22 Innotox market, 2021 - 2040 (USD Million) (Number of Vials Dispensed (000's))
  • Fig. 23 Alluzience market, 2021 - 2040 (USD Million) (Number of Vials Dispensed (000's))
  • Fig. 24 Relfydess market, 2021 - 2040 (USD Million) (Number of Vials Dispensed (000's))
  • Fig. 25 Indication market, 2021 - 2040 (USD Million) (Number of Vials Dispensed (000's))
  • Fig. 26 Aesthetic (Cosmetic) market, 2021 - 2040 (USD Million)
  • Fig. 27 Glabellar lines market, 2021 - 2040 (USD Million)
  • Fig. 28 Forehead lines market, 2021 - 2040 (USD Million)
  • Fig. 29 Crow's feet market, 2021 - 2040 (USD Million)
  • Fig. 30 Facial contouring / masseter reduction market, 2021 - 2040 (USD Million)
  • Fig. 31 Dermotoxin market, 2021 - 2040 (USD Million)
  • Fig. 32 Therapeutic Indications market, 2021 - 2040 (USD Million)
  • Fig. 33 Chronic Migraine market, 2021 - 2040 (USD Million)
  • Fig. 34 Spasticity market, 2021 - 2040 (USD Million)
  • Fig. 35 Cervical Dystonia market, 2021 - 2040 (USD Million)
  • Fig. 36 Blepharospasm market, 2021 - 2040 (USD Million)
  • Fig. 37 Overactive Bladder market, 2021 - 2040 (USD Million)
  • Fig. 38 Hyperhidrosis market, 2021 - 2040 (USD Million)
  • Fig. 39 Ophthalmology market, 2021 - 2040 (USD Million)
  • Fig. 40 Pain Management market, 2021 - 2040 (USD Million)
  • Fig. 41 Others market, 2021 - 2040 (USD Million)
  • Fig. 42 End use market, 2021 - 2040 (USD Million)
  • Fig. 43 Hospitals (Inpatient & Outpatient Care) market, 2021 - 2040 (USD Million)
  • Fig. 44 Specialist Clinics market, 2021 - 2040 (USD Million)
  • Fig. 45 Aesthetic Clinics / MedSpa Chains market, 2021 - 2040 (USD Million)
  • Fig. 46 Botulinum toxin Drugs market revenue, by region
  • Fig. 47 Regional marketplace: Key takeaways
  • Fig. 48 North America Botulinum toxin Drugs market, 2021 - 2040 (USD Million)
  • Fig. 49 U.S. country dynamics
  • Fig. 50 U.S. Botulinum toxin Drugs market, 2021 - 2040 (USD Million)
  • Fig. 51 Canada country dynamics
  • Fig. 52 Canada Botulinum toxin Drugs market, 2021 - 2040 (USD Million)
  • Fig. 53 Mexico country dynamics
  • Fig. 54 Mexico Botulinum toxin Drugs market, 2021 - 2040 (USD Million)
  • Fig. 55 Europe Botulinum toxin Drugs market, 2021 - 2040 (USD Million)
  • Fig. 56 UK country dynamics
  • Fig. 57 UK Botulinum toxin Drugs market, 2021 - 2040 (USD Million)
  • Fig. 58 Germany country dynamics
  • Fig. 59 Germany Botulinum toxin Drugs market, 2021 - 2040 (USD Million)
  • Fig. 60 France country dynamics
  • Fig. 61 France Botulinum toxin Drugs market, 2021 - 2040 (USD Million)
  • Fig. 62 Italy country dynamics
  • Fig. 63 Italy Botulinum toxin Drugs market, 2021 - 2040 (USD Million)
  • Fig. 64 Spain country dynamics
  • Fig. 65 Spain Botulinum toxin Drugs market, 2021 - 2040 (USD Million)
  • Fig. 66 Denmark country dynamics
  • Fig. 67 Denmark Botulinum toxin Drugs market, 2021 - 2040 (USD Million)
  • Fig. 68 Sweden country dynamics
  • Fig. 69 Sweden Botulinum toxin Drugs market, 2021 - 2040 (USD Million)
  • Fig. 70 Norway country dynamics
  • Fig. 71 Norway Botulinum toxin Drugs market, 2021 - 2040 (USD Million)
  • Fig. 72 Asia Pacific Botulinum toxin Drugs market, 2021 - 2040 (USD Million)
  • Fig. 73 Japan country dynamics
  • Fig. 74 Japan Botulinum toxin Drugs market, 2021 - 2040 (USD Million)
  • Fig. 75 China country dynamics
  • Fig. 76 China Botulinum toxin Drugs market, 2021 - 2040 (USD Million)
  • Fig. 77 India country dynamics
  • Fig. 78 India Botulinum toxin Drugs market, 2021 - 2040 (USD Million)
  • Fig. 79 Australia country dynamics
  • Fig. 80 Australia Botulinum toxin Drugs market, 2021 - 2040 (USD Million)
  • Fig. 81 South Korea country dynamics
  • Fig. 82 South Korea Botulinum toxin Drugs market, 2021 - 2040 (USD Million)
  • Fig. 83 Thailand country dynamics
  • Fig. 84 Thailand Botulinum toxin Drugs market, 2021 - 2040 (USD Million)
  • Fig. 85 Latin America Botulinum toxin Drugs market, 2021 - 2040 (USD Million)
  • Fig. 86 Brazil country dynamics
  • Fig. 87 Brazil Botulinum toxin Drugs market, 2021 - 2040 (USD Million)
  • Fig. 88 Argentina country dynamics
  • Fig. 89 Argentina Botulinum toxin Drugs market, 2021 - 2040 (USD Million)
  • Fig. 90 MEA Botulinum toxin Drugs market, 2021 - 2040 (USD Million)
  • Fig. 91 South Africa country dynamics
  • Fig. 92 South Africa Botulinum toxin Drugs market, 2021 - 2040 (USD Million)
  • Fig. 93 Saudi Arabia country dynamics
  • Fig. 94 Saudi Arabia Botulinum toxin Drugs market, 2021 - 2040 (USD Million)
  • Fig. 95 UAE country dynamics
  • Fig. 96 UAE Botulinum toxin Drugs market, 2021 - 2040 (USD Million)
  • Fig. 97 Kuwait country dynamics
  • Fig. 98 Kuwait Botulinum toxin Drugs market, 2021 - 2040 (USD Million)
  • Fig. 99 Company categorization
  • Fig. 100 Company market position analysis
  • Fig. 101 Strategic framework